APA (7th ed.) Citation

R, S., DA, F., CA, F., JLM, C., R, S., T, A., . . . WW, L. (2025). Drug tolerance and persistence to EGFR inhibitor treatment are mediated by an ILK-SFK-YAP signaling axis in lung adenocarcinoma. Oncogene, 44(32), 2831. https://doi.org/10.1038/s41388-025-03461-6

Chicago Style (17th ed.) Citation

R, Shi, et al. "Drug Tolerance and Persistence to EGFR Inhibitor Treatment Are Mediated by an ILK-SFK-YAP Signaling Axis in Lung Adenocarcinoma." Oncogene 44, no. 32 (2025): 2831. https://doi.org/10.1038/s41388-025-03461-6.

MLA (9th ed.) Citation

R, Shi, et al. "Drug Tolerance and Persistence to EGFR Inhibitor Treatment Are Mediated by an ILK-SFK-YAP Signaling Axis in Lung Adenocarcinoma." Oncogene, vol. 44, no. 32, 2025, p. 2831, https://doi.org/10.1038/s41388-025-03461-6.